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Infectious prions contain a self-propagating, misfolded conformer of the prion protein
termed PrPSc. A critical prediction of the protein-only hypothesis is that autocatalytic PrPSc
molecules should be infectious. However, some autocatalytic recombinant PrPSc molecules
have low or undetectable levels of specific infectivity in bioassays, and the essential determinants of recombinant prion infectivity remain obscure. To identify structural and functional
features specifically associated with infectivity, we compared the properties of two autocatalytic recombinant PrP conformers derived from the same original template, which differ by
>105-fold in specific infectivity for wild-type mice. Structurally, hydrogen/deuterium
exchange mass spectrometry (DXMS) studies revealed that solvent accessibility profiles of
infectious and non-infectious autocatalytic recombinant PrP conformers are remarkably
similar throughout their protease-resistant cores, except for two domains encompassing
residues 91-115 and 144-163. Raman spectroscopy and immunoprecipitation studies confirm that these domains adopt distinct conformations within infectious versus non-infectious
autocatalytic recombinant PrP conformers. Functionally, in vitro prion propagation experiments show that the non-infectious conformer is unable to seed mouse PrPC substrates
containing a glycosylphosphatidylinositol (GPI) anchor, including native PrPC. Taken
together, these results indicate that having a conformation that can be specifically adopted
by post-translationally modified PrPC molecules is an essential determinant of biological
infectivity for recombinant prions, and suggest that this ability is associated with discrete
features of PrPSc structure.
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Author Summary
A key prediction of the prion hypothesis is that autocatalytic, misfolded PrPSc molecules
should be highly infectious. Various recombinant PrPSc conformers are able to selfpropagate in vitro, yet paradoxically only some of these conformers possess significant levels of specific infectivity in bioassays. Here we use two closely-matched autocatalytic
recombinant PrP conformers that share the same origin but differ by >105-fold in specific
infectivity to study the molecular basis of prion infectivity. We show that infectious and
non-infectious autocatalytic recombinant PrP conformers have subtle structural differences, and that GPI-anchored PrP substrate molecules can only adopt the infectious PrPSc
conformation. We conclude that post-translational modifications of host PrPC molecules
play a critical role in restricting the range of recombinant PrPSc conformers that are biologically infectious.

Introduction
The conformational conversion of the host-encoded prion protein (PrP) is a central pathogenic
event in the prion diseases [1]. In healthy individuals, PrP adopts a fold that is rich in α-helix,
termed PrPC, and is post-translationally modified by the incorporation of N-linked glycans
and a C-terminal glycosylphosphatidylinositol (GPI) anchor. In individuals suffering from
prion disease, PrPC is misfolded into a β-sheet rich conformation, termed PrPSc, which is capable of acting as a template for the conformational conversion of additional PrPC molecules into
PrPSc. This self-propagating activity of PrPSc is referred to as autocatalysis and is thought to
underlie the infectious nature of the prion diseases. A critical prediction of the protein-only
hypothesis is that autocatalytic PrPSc molecules should be infectious.
A number of in vitro techniques for generating misfolded, autocatalytic PrPSc conformers
have been developed and refined, including the cell-free conversion assay [2] and the serial
protein misfolding cyclic amplification (sPMCA) technique [3,4]. With few exceptions, PrPSc
conformers derived from post-translationally modified, native PrPC substrates have been
highly infectious when bioassayed in wild-type animals [4–8]. In contrast, various autocatalytic
PrPSc conformers derived from recombinant PrP substrates lacking post-translational modifications have displayed large variations in specific infectivity levels as determined by bioassay in
wild-type animals [9–15]. The structural and functional basis of this striking variability in specific infectivity between different autocatalytic recombinant PrPSc molecules remains
unknown.
Recently, using only bacterially expressed recombinant PrP and a single endogenous phospholipid cofactor molecule, phosphatidylethanolamine (PE), as substrates, Deleault et al. successfully produced high titer (2.2 x 106 LD50 U/μg PrP), chemically defined mouse prions in
vitro [10]. Interestingly, it was observed that the prions produced from these minimal components always formed into a single infectious strain with unique, novel biological properties
regardless of the seed originally used to template the in vitro reactions. Importantly, when this
novel prion strain was subsequently propagated in the absence of PE cofactor, a new misfolded
recombinant PrP conformer was produced, which could also self-propagate in sPMCA reactions, but which surprisingly failed to cause disease upon injection into wild-type mice [10].
This new autocatalytic conformer, which we refer to as protein-only PrPSc, therefore had a
>105-fold lower level of specific infectivity as compared to the PrPSc conformer produced in
the presence of PE cofactor, which we refer to as cofactor PrPSc.
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We saw an opportunity to identify structural and functional properties associated with
recombinant PrPSc infectivity by directly comparing these two related PrPSc conformers, which
share the same origin and autocatalytic behavior, but differ strikingly in biological infectivity.

Results
Functional differences between cofactor and protein-only PrPSc can be
localized to their respective C-terminal, protease-resistant cores
Cofactor and protein-only PrPSc are distinct misfolded recombinant PrP conformers that differ
>105-fold in their specific infectivity for wild-type mice [10]. While both of these conformers
demonstrate autocatalytic activity when used to seed sPMCA reactions containing recombinant PrP substrate (Fig 1A and [10]), only cofactor PrPSc also demonstrates autocatalysis when
used to seed sPMCA reactions containing normal brain homogenate as the substrate (Fig 1B
and [10]). The complete failure of protein-only PrPSc to function as a seed for conversion reactions containing native PrPC substrate (Fig 1B, left sample group) provides a logical explanation for this conformer’s lack of infectious activity in vivo, and may apply more generally to
other recombinant PrPSc conformers which demonstrate low levels of specific infectivity in

Fig 1. Cofactor and protein-only PrPSc are stably propagating recombinant PrP conformers that differ in their ability to template the conversion of
native PrPC. (A) Western blot showing three-round sPMCA reactions using recombinant PrP as the substrate and seeded with full-length or PK-digested
cofactor and protein-only PrPSc, as indicated. (B) Western blot showing three-round sPMCA reactions using normal mouse brain homogenate as the
substrate and seeded with full-length or PK-digested cofactor and protein-only PrPSc, as indicated.
doi:10.1371/journal.ppat.1005017.g001
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bioassays. Using cofactor PrPSc as a well-matched control, we therefore sought to gain structural and mechanistic insight into the substrate-dependence of protein-only PrPSc autocatalytic
activity as a means to understand the structural and functional determinants of recombinant
PrPSc infectivity.
To help focus the structural comparison between cofactor and protein-only PrPSc molecules, we first tested whether the protease-resistant cores of both conformers, which contain
approximately two thirds of the residues of mature full-length PrP, have the same substratespecific activity as their respective parent PrPSc molecules in in vitro propagation experiments
(Fig 1). We found that in sPMCA reactions containing recombinant PrP substrate and defined
cofactors, both full-length and truncated cofactor and protein-only PrPSc molecules function
as competent seeds which faithfully propagate the characteristic PK-resistant bands associated
with their parent PrPSc molecules (Fig 1A) [10]. Moreover, in in vitro conversion reactions
containing native, brain-derived PrPC substrate we found that full-length and PK-digested
cofactor PrPSc drive the conversion of native PrPC (Fig 1B, third and fourth panels), while fulllength and truncated protein-only PrPSc do not (Fig 1B, first and second panels), indicating
that functional differences in the in vitro activity of cofactor and protein-only PrPSc molecules
can be localized to the PK-resistant core. Epitope mapping of the cofactor and protein-only
PrPSc PK-resistant cores (S1 Fig), revealed that both are C-terminal PrP fragments that include
the 6D11 epitope (residues 93–109, with 97–100 as the major determinants of binding [16])
(S1 Fig, top panel) and the extreme C-terminus (S1 Fig, bottom panel). Based on these results,
we focused our subsequent structural analyses on C-terminal residues beginning at glycine 89
(G89), the primary PK-cleavage site for PrPSc 27–30 [17].

Structural comparison of cofactor and protein-only PrPSc by DXMS
identifies conformational differences in restricted C-terminal domains
To compare the structures of cofactor PrPSc and protein-only PrPSc molecules, we performed
hydrogen/deuterium exchange MS (DXMS) on these two conformers generated in parallel
from the same OSU prion strain seed (Fig 2A). The OSU prion strain was originally synthesized by Wang et al. using recombinant PrP, total liver RNA and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) [15], and it has previously been referred to as the OSU strain
by Deleault et al. [10]. OSU-seeded cofactor and protein-only PrPSc samples used for structural
analysis in this study were generated with high conversion efficiency in sPMCA (S2 Fig) and
then purified prior to DXMS analysis by a series of ultracentrifugation steps described in Materials and Methods. Co-sedimentation of significant quantities of non-specifically aggregated,
protease-sensitive PrP was ruled out in the OSU-seeded cofactor PrPSc DXMS sample due to
its near complete conversion to PK-resistant PrPSc (96% PK-resistant conversion efficiency, S2
Fig). To assess the potential contribution of non-specifically aggregated, protease-sensitive PrP
to the OSU-seeded protein-only PrPSc sample analyzed by DXMS (77% PK-resistant conversion efficiency, S2 Fig), we mock-seeded protein-only PMCA reactions and subjected the
resulting material to the DXMS purification protocol (S3 Fig, top panel). We did not detect any
non-specifically aggregated PrP in these mock-seeded PMCA reactions (S3 Fig, top panel, samples S0 vs P3), indicating that the protein-only PrPSc DXMS sample does not contain appreciable quantities of non-specifically aggregated, protease sensitive PrP.
Regional solvent accessibility of cofactor and protein-only PrPSc was determined by incorporating deuteration data from 188 overlapping C-terminal peptides (Fig 2C) recovered in a
representative experiment from each deuterium-labeled PrPSc sample. This high density of
overlapping deuterated peptides provides PrPSc solvent accessibility measurements with resolution down to segments of ~5 amino acids. In examining and discussing the results of this
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Fig 2. Regional solvent accessibility of cofactor and protein-only PrPSc conformers. Purified PrPSc conformers were incubated in D2O-containing
exchange buffer for 30 min, 2 h, or 24 h and the reaction products were quenched and subjected to LC/MS to measure peptide-specific deuterium
incorporation. Data from overlapping peptides was used to quantify localized deuterium exchange and construct ribbon diagrams from a representative
experiment. (A) Regional solvent accessibility comparison between cofactor and protein-only PrPSc conformers derived from the same OSU prion strain. The
discontinuous epitope of mAb 15B3, which selectively binds infectious PrPSc, is indicated with black bars [18]. (B) Regional solvent accessibility of two
additional cofactor PrPSc conformers, derived from the 301C and ME7 prion strains. (C) Map of the 188 high quality deuterated peptides, including different
peptide charge states, identified in all four PrPSc experimental samples and used to construct ribbon diagrams in parts (A) and (B). Alternating shades of blue
in part (C) are used to highlight neighboring peptides. Despite complete coverage of amino acids 89–230 by overlapping peptides, gaps exist in the ribbon
diagrams shown in parts (A) and (B) for two reasons: 1. Deuterium incorporation cannot be quantified for the two N-terminal residues of a peptide as a result
of rapid back exchange [19], and 2. Proline residues lack amide hydrogen atoms and therefore do not contribute to deuterium incorporation measurements.
doi:10.1371/journal.ppat.1005017.g002
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study, specific regions of the PrP primary sequence are referred to either by explicit residue
numbering, based on the mouse PrP sequence, or with reference to the location of known secondary structural elements in monomeric, α-helical recombinant PrP (α-PrP). For example,
the domain corresponding to residues 178–216 could also be described as α2-α3 because it
encompasses the second and third α-helices in α-PrP.
The C-terminal cores of cofactor and protein-only PrPSc are both substantially protected
from solvent exchange (Fig 2A) as compared to α-PrP (S4 Fig). This solvent protection is consistent with widespread conversion to β-sheet secondary structure and/or the formation of
large solvent-excluding aggregates [20]. Within the misfolded, solvent-protected PrPSc core
there are large regions in which cofactor PrPSc and protein-only PrPSc have remarkably similar
solvent accessibility profiles—in particular, the regions containing residues 118–143 and 165–
230. However, there are also specific domains in which the cofactor and protein-only conformations can be distinguished by solvent accessibility. Most clearly, the domain encompassing
residues 144–163, corresponding to α1 and β2 in α-PrP [21], is more solvent-exposed in protein-only PrPSc than in cofactor PrPSc (Fig 2A). The relatively exposed structure of the α1-β2
domain was preserved, and in fact accentuated, in an independently prepared protein-only
PrPSc sample (S5 Fig). In addition, residues 91–110 appear to be slightly more exposed in protein-only PrPSc than in cofactor PrPSc while residues in the palindromic region (amino acids
111–120) are more obviously protected in protein-only PrPSc. Differences in these relatively Nterminal regions may contribute to the differing susceptibility to PK cleavage observed for the
cofactor and protein-only PrPSc conformations (Fig 1 and S1 and S2 Figs).

Convergence of biological strain properties is correlated with cofactor
PrPSc structural convergence
Deleault et al. [10] originally used three prion strains with distinct infectious phenotypes to
seed the chemically-defined, recombinant PrP conversion system used to produce cofactor and
protein-only PrPSc molecules. Interestingly, the three input strains converged into a single
strain with a novel biological phenotype upon propagation in sPMCA reactions containing
only recombinant PrP substrate and a single cofactor. We used DXMS to examine the structures of the two additional cofactor PrPSc samples generated by Deleault et al. in sPMCA reactions that were initially seeded with mouse prion strains distinct from the OSU strain (301Cand ME7-seeded cofactor PrPSc) (Fig 2B). The results revealed that the PK-resistant cores of all
three cofactor PrPSc molecules have nearly identical solvent accessibility profiles (Fig 2A and
2B), consistent with convergence into a single cofactor PrPSc conformation. As was the case
with OSU-seeded cofactor and protein-only PrPSc, we assessed the contribution of non-specifically aggregated, protease-sensitive PrP to the DXMS data for 301C- and ME7-seeded cofactor
PrPSc by determining sample conversion efficiency (S2 Fig) and performing a mock-seeding
experiment (S3 Fig, bottom panel). 301C-seeded cofactor PrPSc is almost entirely converted to
PK-resistant PrPSc (99% PK-resistant conversion efficiency, S2 Fig), ruling out any significant
contribution of non-specific PrP aggregation to the presented DXMS data. Mock-seeding of
cofactor-supplemented PMCA reactions resulted in the recovery of approximately 8% of the
starting material as non-specifically aggregated, protease-sensitive PrP (S3 Fig, bottom panel,
samples S0 vs P3). For ME7-seeded cofactor PrPSc (82% PK-resistant conversion efficiency,
S2 Fig), we therefore estimate that such non-specifically aggregated PrP accounts for no more
than 2% of the sample analyzed by DXMS (ie. 8% of the unconverted, PK-sensitive material
yields the estimate for non-specifically aggregated, PK-sensitive PrP, or ~1.4% of the total
input PrP, which is then divided by the sum of the PK-resistant and PK-sensitive insoluble
PrP, or ~83.4% of the total input PrP).
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The data from cofactor PrPSc and protein-only PrPSc sample replicates were aggregated,
yielding 63 shared peptides for which individual deuteration curves could be plotted (S6 and
S7 Figs). Interestingly, peptides that include residues N-terminal to G89 were less frequently
recovered and showed irregular deuteration profiles specifically in cofactor PrPSc samples
(S6 and S7 Figs).

Domain-specific conformational differences between cofactor and
protein-only PrPSc are supported by immunoprecipitation and Raman
spectroscopy studies
Having identified the α1-β2 domain by DXMS as a region of conformational divergence in our
cofactor and protein-only PrPSc samples, we sought to confirm this finding using additional
biochemical and biophysical approaches. The α1-β2 region contains a portion of the epitope for
15B3, a well-characterized PrPSc-specific conformational antibody [18]. The regions of PrP primary structure that comprise the discontinuous 15B3 epitope are shown schematically in Fig
2A. In a single immunoprecipitation experiment, 15B3 efficiently pulled down all three of our
cofactor PrPSc samples (Fig 3, top three panels), but only weakly bound protein-only PrPSc
(Fig 3, bottom panel), indicating a disruption of the 15B3 conformational epitope, consistent
with our DXMS results.
We further sought to confirm a conformational difference between cofactor and proteinonly PrPSc in the α1-β2 domain using Raman spectroscopy (Fig 4). Analysis of the Raman spectra acquired from these two conformers identified multiple Raman shifts that could be assigned
to tyrosine residues, which are plentiful in the PrP C-terminus and specifically enriched in the
α1-β2 domain (6 of 11 total C-terminal tyrosines). By Raman spectroscopy, protein-only PrPSc
appears to contain more exposed tyrosine residues than cofactor PrPSc as evidenced from the
increased ring ν(C = C) intensity at ~1620 cm-1 (Fig 4, left panel), the 850 cm-1/830 cm-1
ratio being greater than 1 (Fig 4, right panel) [22], and the increased ring ν(CH) intensity at
~3075 cm-1 (S8 Fig, left panel) [23,24], consistent with our DXMS results. In addition, and also

Fig 3. Immunoprecipitation with conformation-specific mAb 15B3 distinguishes between cofactor
and protein-only PrPSc. Converted sPMCA products were purified by ultracentrifugation with nOG washes
to remove unconverted α-PrP and excess lipid, and immunoprecipation was performed using 15B3-coated or
uncoated rat anti-mouse IgM-conjugated magnetic beads, as indicated. The location of the discontinuous,
15B3 conformational epitope is shown in Fig 2A. Arrows indicate an Mr of ~23 kDa, the expected mobility of
full-length recombinant PrP. By densitometry, the efficiency of 15B3 immunoprecipitation in this experiment is
79%, 71% and 74% for 301C-seeded, ME7-seeded, and OSU-seeded cofactor PrPSc, respectively, and 15%
for OSU-seeded protein-only PrPSc.
doi:10.1371/journal.ppat.1005017.g003
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Fig 4. Raman spectroscopy of cofactor and protein-only PrPSc, focusing on spectral regions assigned to tyrosine side chains. The primary
sequence of the region examined by DXMS is shown, with residues 144–163 boxed and tyrosine residues highlighted in green. Raman shifts corresponding
to the ν(C = C) ring mode (~1620 cm-1) and the tyrosine Fermi-doublet (~850 and 830 cm-1) are shown.
doi:10.1371/journal.ppat.1005017.g004

consistent with our DXMS data, protein-only PrPSc appears to contain more exposed CNH
groups than cofactor PrPSc as indicated by the increased intensity in the 1530–1580 cm-1
Amide II region, corresponding to ν(CN) and δ(CNH) Raman shifts (S8 Fig, right panel), as
well as an increased ν(CN) intensity at ~3300 cm-1 (S8 Fig, left panel). These exposed CNH
groups likely originate from the 4 exposed arginine (R) and single exposed glutamine (Q),
asparagine (N) and tryptophan (W) residues in the α1-β2 domain, or from CNH-containing
side chains in the N-terminal portion of the PK-resistant PrPSc core (residues ~91–115).

Cofactor and protein-only PrPSc differ functionally in the ability to convert
GPI-anchored substrates
Our DXMS data suggests that structural differences between cofactor and protein-only PrPSc
are limited to specific domains (Fig 2A) and that these structural differences affect the ability of
recombinant PrPSc to convert native PrPC (Fig 1B). As conversion substrates, α-PrP and native
PrPC share the same primary sequence, but PrPC also contains bulky N-linked glycans and a
GPI anchor as post-translational modifications. Therefore, we hypothesized that limited conformational differences might dramatically alter a recombinant conformer’s infectious activity
by impinging on spatial regions that would be occupied by N-linked glycans or a GPI anchor
should PrPC adopt the same conformation. To test this hypothesis, we partially purified native
PrPC and performed enzymatic deglycosylation with PNGase F. The resulting PrPC molecules,
which uniformly contain a GPI anchor as the sole post-translational modification, were used as
the substrate in sPMCA experiments seeded with cofactor and protein-only PrPSc (Fig 5 and
repeated in S9 Fig). Like brain-derived prions, recombinant cofactor PrPSc was able to template
the conversion of unglycosylated PrPC (Fig 5 and S9 Fig, middle and right sample groups),
whereas protein-only PrPSc failed to function as an autocatalytic seed in the same substrate
(Fig 5 and S9 Fig, left sample group). Note that initial conversion of unglycosylated PrPC substrate molecules to a PK-resistant form was detected after seeding with both cofactor and protein-only PrPSc and 24 h of intermittent sonication, as indicated by the appearance of PK
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Fig 5. Cofactor and protein-only PrPSc differ in their ability to template the conversion of PrP substrates containing a GPI anchor. Western blot
showing three round sPMCA reactions using partially purified and deglycosylated PrPC as the substrate and seeded with protein-only PrPSc, cofactor PrPSc,
or prion-infected brain homogenate, as indicated. A replicate of this experiment is shown in S9 Fig
doi:10.1371/journal.ppat.1005017.g005

digestion products of slightly higher apparent molecular weight than the respective input seeds
(Fig 5 and S9 Fig, left and middle sample groups, round 1 vs 0). In the case of protein-only
PrPSc, this higher molecular weight product is diluted out in proportion to the initial seed
(Fig 5 and S9 Fig, left sample group, round 2 vs 1), suggesting stoichiometric, as opposed to
autocatalytic, PrP conversion. In contrast, the higher molecular weight band generated from
infectious PrPSc seed was able to propagate independently of the initial PrPSc seed, suggesting
autocatalytic PrP conversion (Fig 5 and S9 Fig, left and middle sample groups, rounds 1–3).
This result indicates that the existence of bulky N-linked substrate glycans is not solely responsible for the failure of recombinant protein-only PrPSc to function as a seed for native PrPC.
Moreover, by isolating the effect of a single substrate post-translational modification on recombinant PrPSc function, this result provides proof of principle that such modifications may
impair the efficient replication of certain recombinant PrPSc conformers in vivo.

Discussion
A misfolded conformer of the prion protein, PrPSc, is an essential, and possibly the sole, component of infectious prions [1]. Although PrPSc is known to be rich in β-sheet [25–27], a highresolution structure of this PrP conformer is lacking, and the structural features of PrPSc that
determine its infectious activity remain obscure.
Recently, Deleault et al. used a chemically-defined, minimal PrP conversion system and
identical seeding material to generate two distinct, autocatalytic recombinant PrPSc conformers
that differ >105-fold in their specific infectivity [10]. One recombinant conformer, produced
in the presence of PE cofactor molecules and termed cofactor PrPSc, had a titer in normal
C57BL mice nearly equivalent to that of brain-derived PrPSc (2.2 x 106 LD50 U/μg PrP), while
the other conformer, produced in the absence of cofactor molecules and termed protein-only
PrPSc, failed to cause disease in the same host, even at the most concentrated dose tested. In the
present study, we have taken advantage of the uniquely controlled opportunity presented by
these two PrPSc conformers, which share the same origin and autocatalytic behavior but differ
strikingly in their biological activity, in order to investigate the structural and functional determinants of recombinant PrPSc infectivity.

PLOS Pathogens | DOI:10.1371/journal.ppat.1005017 June 30, 2015
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By comparing the structures of these two conformers using DXMS, we find that cofactor
and protein-only PrPSc molecules have remarkably similar solvent accessibility profiles within
the PK-resistant PrPSc core (Fig 2A). Indeed, they are virtually indistinguishable by this measure in the domains that correspond roughly to α2-α3 in α-helical PrP (~ residues 165–230),
and to the stretch of residues between the hydrophobic domain and the start of α1 (~118–143)
(Fig 2A), both displaying significant protection from solvent exchange, consistent with widespread conversion to β-sheet secondary structure. The degree of solvent protection, especially
N-terminal to β2, distinguishes cofactor and protein-only PrPSc from synthetic PrP amyloids
[27–31], and is most consistent with previous DXMS studies using brain-derived and recombinant prions [27,32,33]. Like these recent DXMS studies, the data from the present study are
consistent only with those models of PrPSc structure that involve a complete refolding of the
PrPC C-terminal α-helices to β-sheet—for example, the parallel in-register β-sheet architectures proposed by Cobb et al. [34] and more recently by Groveman et al.[35]. Interestingly, the
modest increase in solvent accessibility seen at residues 187–196 in all four PrPSc conformers
studied here (Fig 2) corresponds well with the proposed loop of the native disulfide hairpin
predicted by both of these models.
In addition to broad similarities between cofactor and protein-only PrPSc in solvent accessibility, we have identified two specific domains in which the cofactor and protein-only PrPSc
conformers can be conformationally distinguished: most clearly within the domain that corresponds to α1 through the C-terminus of β2 in PrPC (~ residues 144–163), but also within a
domain at the N-terminus of the PK-reistant core, comprising residues ~91–115 (Fig 2A). In
both of these domains, protein-only PrPSc appears to be more exposed to solvent exchange
than cofactor PrPSc. Given the role PE cofactor molecules play in the formation of cofactor, but
not protein-only, PrPSc [10], it is likely that the relatively solvent-protected structural features
selectively associated with cofactor PrPSc are cofactor-induced. Moreover, the fact that the PKresistant cores of all three cofactor PrPSc samples, derived from distinct prion strains but propagated in the same chemically-defined system, are highly similar (Fig 2A and 2B) suggests that
the convergence of biological strain properties observed by Deleault et al. [10] is associated
with a convergence of PrPSc structure.
The α1-β2 domain, which appears to adopt different conformational states in cofactor and
protein-only PrPSc (Figs 2–4), has previously been identified as a region of PrP that has important implications for PrP misfolding. For example, several PrPSc-selective conformational antibodies are known to have epitopes that reside within this domain [18,36], and small deletions
towards the C-terminus of this domain produce PrP molecules that do not readily form PrPSc
and, in fact, function as dominant-negative inhibitors of PrPSc replication in full-length PrP
substrates [37]. Moreover, in the complete absence of the α1-β2 domain, a redacted ‘miniprion’
is capable misfolding to form PrPSc, but does not cause disease when inoculated into animals
expressing full-length PrP [38,39]. Interestingly, the α1-β2 domain lies adjacent the β2-α2 loop,
a region of PrP known to play an important role in prion formation and interspecies prion
transmission [40–43].
Less is known about the second domain (amino acids ~91–115) in which cofactor and protein-only PrPSc appear to adopt different conformational states (Fig 2 and S5 Fig). This domain
includes the so-called ‘fifth site’ for Cu2+ binding [44–46].
It is important to acknowledge that any comparisons drawn between DXMS results in the
present study and the activities of cofactor and protein-only PrPSc are correlations only, and
that it is possible the structural features underlying PrPSc-associated activities such as autocatalysis and infectivity may be subtle and/or beyond the resolution of the DXMS approach. Similarly, it should be acknowledged that DXMS provides a measure of the average deuterium
incorporation at a given amide proton position over a population of PrPSc molecules. It has
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been proposed that PrPSc exists as a heterogeneous conformational mixture of so-called quasispecies [47], but it is not known—for the recombinant PrPSc conformers studied here, or any
other PrPSc preparation—what proportion of PrPSc molecules exhibit autocatalytic or infectious activity. Therefore, the solvent accessibility profiles obtained in this study are representative of conformational differences at a PrPSc population level, and may not be representative of
rare, and potentially biochemically/biologically active, components within a given PrPSc sample. In addition, it should be made clear that when interpreting ribbon diagrams, as in Fig 2,
similar solvent accessibility profiles do not guarantee similar tertiary and/or quaternary structures, although by using a set of matched peptides with dense, overlapping coverage of the
region of interest (Fig 2C) to compare the solvent accessibility of the cofactor and protein-only
PrPSc conformers, we have increased confidence in such an interpretation of the data. Finally,
we do not claim that a relatively solvent inaccessible conformation of either of the two structurally divergent domains identified in the present study is required for PrPSc infectivity generally.
The data presented here are specific to the situation in which seed and substrate are both of the
mouse PrP sequence, and it is possible that different PrP sequences may have different infectivity-associated conformational spaces. Consistent with a sequence-specific interpretation of our
results, it has previously been shown that native mouse prions also appear to have a relatively
solvent-protected structure in the α1-β2 domain [27], while a recent study showed that this
same domain is relatively solvent exposed in native human prions [33].
The dissociation of in vitro autocatalytic activity and infectivity seen in some, but not all,
recombinant PrPSc conformers [10,14,15] presents an interesting functional question: why is it
that a PrPSc conformer capable of self-replication in recombinant PrP substrate fails to function
as a template for native PrPC conversion in vivo? One obvious possibility relates to substrate
complexity: although α-PrP and native PrPC share similar secondary structures [21,48], native
PrPC is a more complex conversion substrate due to the post-translational addition of N-linked
glycans and a GPI anchor, and due its location within the membrane environment of cells.
Using our cofactor and protein-only recombinant PrPSc seeds as a controlled pair, we performed in vitro conversion experiments in which we, in a step-wise manner, modified native
PrPC substrate to make it more and more like α-PrP in an effort to identify the factor(s) that
prevent protein-only PrPSc from converting PrPC in vivo. Remarkably, the functional difference between cofactor and protein-only PrPSc persisted even after extracting native PrPC from
the membrane environment (Fig 1B and [10]) and removing all N-linked glycans (Fig 5 and S9
Fig), suggesting that neither of these factors is responsible for preventing protein-only PrPSc
from converting native PrPC in vivo. Unfortunately, the complementary experiment, in which
the GPI anchor of PrPC is selectively removed and that modified PrPC substrate used in conversion reactions is not possible for two reasons: 1. Delipidated PrPC is a poor conversion substrate, even for sPMCA experiments seeded with native prions [49], and 2. Detection of
delipidated GPI-anchored proteins by Western blotting is technically challenging [50]. Nevertheless, we infer from the available data that the functional difference between cofactor and
protein-only PrPSc is mostly likely attributable to differing abilities of these two conformers to
template the conversion of wild-type mouse PrP substrates containing a GPI anchor. Interestingly, Kim et al. have previously demonstrated that the GPI anchor plays an important role in
the in vitro formation of native PrPSc conformers [49].
To integrate the results of our structural and functional comparison of cofactor and protein-only PrPSc, we propose a model to account for the striking variation in specific infectivity
observed for recombinant PrPSc conformers [9–15] (Fig 6). In this model, the PrP polypeptide
backbone, represented by recombinant PrP, is capable of adopting a wide variety of autocatalytic conformations. However, post-translationally modified, native PrPC can only adopt a subset of these conformations, and this subset represents the infectious recombinant PrPSc
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Fig 6. Proposed model, supported by structural and functional data in the present study, to explain
variation in specific infectivity between different recombinant PrPSc conformers. Recombinant PrP,
which lacks post-translational modifications, has fewer conformational constraints than native PrPC and can
adopt a variety of autocatalytic PrPSc conformations. Only those autocatalytic PrPSc conformers that can also
structurally accommodate the post-translational modifications of native PrPC–in the case of the conformers
studied presently, a substrate GPI anchor—are capable of biological infectivity. G = N-linked glycan;
GPI = GPI anchor.
doi:10.1371/journal.ppat.1005017.g006

conformers. From previous studies of PrP and other proteins, there is evidence to suggest that
post-translational modifications can alter or restrict protein folding pathways. Indeed, Nlinked glycans are known broadly to have chaperone-like effects and to contribute to protein
stability [51]. In the case of PrP, it has been observed that the presence of glycans can alter the
rate of amyloid fibril formation [52,53], and that by restricting available PrP glycoforms it is
possible to control prion strain susceptibility [54]. Whether GPI anchors play a role in protein
folding or misfolding is less clear. The loss of the GPI anchor of PrP (which is concomitant
with a significant reduction in PrPC glycosylation in vivo [55]) appears to have only a modest
effect on PrPSc structure [56], but substantially alters the biochemical properties of PrPSc and
promotes the formation of fibrillar aggregates [57,58] and interferes with PrPSc replication in
vitro [49]. Interestingly, the co-expresssion of anchorless and wild-type PrPC molecules in vivo
appears to enhance host susceptibility to recombinant PrP amyloid fibrils [59], while the experimental addition of a GPI anchor to the amyloidogenic yeast protein, Sup35p, prevents the formation of fibrillar structures, leading instead to the formation of PrPSc-like, non-fibrillar
aggregates [60]. While the data from the present study specifically point to a role for the GPI
anchor of native mouse PrPC in restricting the range of recombinant PrPSc conformers that
possess infectious activity, we cannot exclude the possibility that N-linked glycans also influence the infectivity-associated recombinant PrPSc conformational space. In fact, we speculate
that the boundaries of this subset of the conformational space are likely to be highly contextdependent, determined by a complex interplay between the polypeptide sequence of a given
PrPC substrate molecule and all of its associated post-translational modifications.
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In conclusion, we report for the first time a structural and functional comparison between
two autocatalytic recombinant PrPSc conformers that share the same origin and biochemical
behavior, but differ >105-fold in infectious titer for wild-type mice. Based on our findings, we
suggest that those autocatalytic recombinant PrPSc conformers which are also highly infectious
contain specific structural features in a limited number of PrP domains, and that these features
may be required in order to accommodate specific substrate post-translational modifications
during native PrPC misfolding in vivo.

Materials and Methods
Preparation of cofactor and protein-only PrPSc by sPMCA
Cofactor and protein-only PrPSc [10]were generated by sPMCA as described [10]. Briefly, 100–
200 ul reactions containing 6 μg/ml recombinant mouse PrP 23–230 (recombinant PrP) in
conversion buffer [20 mM Tris (pH 7.5), 135 mM NaCl, 5 mM EDTA (pH 7.5), 0.15% Triton
X-100] were supplemented with either brain-derived cofactor [10] for cofactor PrPSc propagation, or water for protein-only PrPSc propagation. Reactions were seeded with 1/10th volume of
converted cofactor or protein-only PrPSc PMCA product and sonicated with 15-s pulses every
30 min for 24 h at 37°C. After 24 h of PMCA, 1/10th volume of the reaction was used to seed
fresh substrate cocktail and the 24 h sonication program was repeated. PMCA reactions were
sonicated in microplate horns using a Misonix S-4000 power supply (Qsonica) set to amplitude
50–60. Sample tubes were sealed with Parafilm (Bemis Company) and the sonicator horn was
soaked in 100% bleach prior to switching to propagation of a different PrPSc species in order to
prevent cross-contamination.

Detection of cofactor and protein-only PrPSc
Formation of cofactor and protein-only PrPSc was monitored by digestion of PMCA samples
with proteinase K (PK) and Western blotting. Samples were treated with 25 μg/ ml PK (Roche)
for 30 min at 37°C, and digestion reactions quenched by the addition of SDS-PAGE loading
buffer and heating to 95°C for 10 min. SDS-PAGE and Western blotting were performed as
described previously [10] using mAb 27/33, unless otherwise specified.

Purification and epitope mapping of cofactor and protein-only PrPSc PKresistant cores
All centrifugation was done at 4°C. Cofactor and protein-only PrPSc PMCA products were
treated or mock-treated with PK as described above and the reaction quenched by the addition
of PMSF to 5 mM final concentration. To remove PK, excess lipids, and any soluble recombinant PrP digestion products, digested PrPSc was washed twice with nOG wash buffer (1% noctyl-beta-D-glucopyranoside (nOG), 150 mM NaCl, 8.3 mM Tris pH 7.2) by centrifugation at
100,000 rcf for 1 h, with resuspension by sonication (60-s pulse, 70 amplitude) followed by
brief vortexing. After the second wash, samples were pelleted by centrifugation at 100,000 rcf
for 1 hr and resuspended in conversion buffer by sonication and vortexing to a recombinant
PrP concentration of 6 μg/ml for use in epitope mapping and sPMCA experiments.
Epitope mapping of the cofactor and protein-only PrPSc PK-resistant cores was performed
using mAbs 6D11 [61] and R2 [62]. Aliquots of identical purified samples were run on
SDS-PAGE, transferred to PVDF membrane, and processed independently by Western blotting using trays and containers that had never been in contact with anti-PrP antibodies.
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sPMCA with native PrPC and deglycosylated PrPC substrates
For normal brain homogenate sPMCA, brain homogenates were prepared at 10% (w/v) in conversion buffer (PBS containing 1% (v/v) Triton X-100 and cOmplete protease inhibitor cocktail
(Roche)) from healthy C57BL/6 mice, as described by Castilla et al. [5]. Homogenates were
clarified by brief sonication (F60 Sonic Dismembrator (Fisher Scientific), three 5-s pulses at
~1.8 amplitude), followed by centrifugation at 500 rcf for 15 min. Clarified substrates were
then seeded with 1/10th volume of purified PrPSc samples, and sPMCA carried out as described
above, with 20-s sonication pulses every 30 min.
For deglycosylated PrPC sPMCA, diglycosylated native PrPC was first purified from normal
mouse brain and then fully deglycosylated by treatment with PNGase F (New England Biolabs)
as described [63]. Deglycosylated PrPC sPMCA reactions [63] were seeded with 5% (v/v) of
recombinant or brain-derived PrPSc and sonicated as described above for normal brain homogenate sPMCA.

Deuterium exchange and quenching of cofactor and protein-only PrPSc
All centrifugation was done at 4°C. Samples were prepared for deuterium exchange as
described previously [32] with the following modifications. For each PrPSc species, converted
PMCA cocktail was washed twice with nOG wash buffer (1% n-octyl-beta-D-glucopyranoside
(Anatrace), 150 mM NaCl, 8.3 mM Tris pH 7.2) by centrifugation at 100,000 rcf for 1 h, with
resuspension by 60 s of sonication at 70 amplitude followed by brief vortexing. After the second
wash, samples were pelleted by centrifugation at 100,000 rcf for 1 hr and resuspended in a volume of mock labeling buffer (150 mM NaCl, 8.3 mM Tris, pH 7.2) by sonication and vortexing
immediately prior to the initiation of deuterium exchange. Deuterium exchange was initiated
by the addition an equal volume of labeling buffer (D2O containing 150 mM NaCl, 8.3 mM
Tris, pH 7.2, where pH is the pH meter reading without taking into account the hydrogen
isotope effect) and samples were incubated at room temperature (22°C). During the last 30
min of labeling, samples were pelleted by centrifugation at 100,000 rcf. Labeling buffer was
removed and the samples were quenched on ice for 2 min with ice-cold quench buffer [0.8%
formic acid, 6.4 M guanidine hydrocholride, 150 mM tris(2-carboxyethyl)phosphine (TCEP)
(Pierce)]. Quenched samples were diluted with 3 volumes of ice-cold acid diluent (0.8% formic
acid, 16.6% glycerol), transferred to chilled autosampler microvials, frozen on crushed dry ice,
sealed and stored at -70°C until analysis. For all PrP samples, including those described below,
Western blotting of quenched material was performed and confirmed the presence of 1–2 μg
recombinant PrP per sample vial.

Deuterium exchange and quenching of α-helical recombinant PrP and
preparation of equilibrium-deuterated controls
Deuterium exchange and quenching of normally folded, α-helical recombinant PrP (α-PrP)
was performed as described above for cofactor and protein-only PrPSc, with the following modifications. Recombinant PrP was resuspended to 1.0 mg/ml in water and an equal volume of 2x
labeling buffer (D2O containing 300 mM NaCl, 16.6 mM Tris, pH 7.2) was added to initiate
deuterium exchange. Thirty minutes prior to quenching, an aliquot of the labeling reaction was
placed at 4°C to replicate the temperature change experienced by PrPSc samples during centrifugation. Deuterium-labeled α-PrP was then quenched on ice for 2 min by the addition of 1.25
volumes of ice-cold quench buffer containing 700 mM TCEP. To the quenched samples was
added 1.30 volumes of ice-cold acid diluent prior to aliquoting into autosampler microvials
and freezing on dry ice, as described above.
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Equilibrium-deuterated samples were prepared by resuspension of recombinant PrP in 2.5
or 6.0 M guanidine hydrochloride solution containing a 1:1 molar ratio of protons:deuterons
by mixing appropriate quantities of H2O, D2O, guanidine HCl and guanidine (D6) DCl (Cambridge Isotope Laboratories, Andover, MA). Deuterium exchange was allowed to proceed for
72 hours at room temperature (22°C) prior to quenching as described above for α-PrP.

Quantification of co-sedimentation of protease-sensitive, insoluble PrP
in DXMS PrPSc samples
To estimate the fraction of non-specifically aggregated PrP that could potentially co-sediment
during the purification of PrPSc samples for DXMS, mock-seeded PMCA reactions were performed using PMCA cocktail supplemented with brain-derived cofactor or water. After 24 h of
PMCA, the mock-seeded PMCA reactions were purified by ultracentrifugation as described
above for DXMS samples and the fraction of the input PrP that was recovered as non-specifically aggregated, insoluble PrP was quantified by Western blot.

Analysis of deuterium incorporation
Measurement of deuterium incorporation by LC-MS was performed as described previously
[32], with the following modifications. Samples were loaded onto the in-line immobilized fungal protease XIII column at a rate of 60 μl/min, allowed to digest for 3 min, and then pushed
onto the in-line immobilized pepsin column at a rate of 20 μl/min. Peptides were collected during pepsin digestion on a C18 trap column (Michrom MAGIC C18AQ, 0.2x2) preceding the
C18 resolving column (Michrom MAGIC C18AQ, 0.2x50). All measurements were made on
an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific), and data was analyzed as
described previously [32].

Immunoprecipitation of cofactor and protein-only PrPSc with mAb 15B3
Rat anti-mouse IgM-conjugated Dynabeads (Life Technologies) were washed according to the
manufacturer’s protocol and coated with mAb 15B3 (Prionics) at 5 μg per 10 μl beads with gentle mixing at room temperature for 2 h. Coated beads were washed three times to remove
unbound antibody and stored at 4°C for no more than one week prior to use. Converted cofactor or protein-only PrPSc PMCA cocktail was washed twice with nOG wash buffer as described
above for the preparation of samples for DXMS. After the second wash, samples were collected
by centrifugation at 100,000 rcf for 1 hr at 4°C and the pellet was gently washed with Prionics
homogenization buffer (Prionics). Samples were then centrifuged at 100,000 rcf for 10 min at
4°C and the supernatant discarded. The pellet was resuspended in Prionics homogenization
buffer by sonication (30-s pulse, 70 amplitude) and vortexing to a final concentration of
~60 ng/μl PrP. For each PrPSc sample, ~250 ng PrP was added to 0.5 ml Prionics IP buffer
(Prionics) and to this was added 10 μl of beads that were either coated with 15B3 or uncoated.
Samples were allowed to interact with the beads at room temperature for 4 h with gentle mixing, followed by two washes with Prionics IP buffer and resuspension of the beads in 2x
SDS-PAGE loading buffer. Samples were incubated at 95°C for 10 min, briefly centrifuged to
concentrate the beads and the supernatant was collected for analysis by Western blot.

Raman spectroscopy of cofactor and protein-only PrPSc
Cofactor and protein-only PrPSc were generated by sPMCA supplemented with synthetic plasmalogen PE (Avanti Polar Lipids) as the sole cofactor, as described previously [64]. Converted
PMCA cocktail was digested with PK as described above and quenched by the addition of
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PMSF (Sigma Aldrich) to 2 mM final concentration. Digested samples were washed twice with
nOG wash buffer, as described above, and then twice with water to remove residual buffer
components and detergent. Samples were then resuspended in water to a concentration of
~140 ng/μl PrP by vortexing and a 15-s sonication pulse. 10 μl of the resulting sample was spotted onto a glass slide and allowed to dry under a stream of nitrogen. Once dry, another 10 μl
was spotted on top of the first and again allowed to dry under nitrogen. Spotted samples were
scanned using a WITec CRM200 Raman confocal light microscope, equipped with a 100x lens
and a 514 nm argon laser with 45 mW output. An f/4, 300 mm imaging spectrograph was
employed with 2 exit ports and a 600 lines/mm grating, with a Peltier-cooled CCD, 1340 x 100
pixel format, and a 16-bit camera controller. The fiber optic connecting the microscope with
the spectrograph was 50 μm in diameter. Spectra were acquired using an integration time of
8 s, with two hardware and two software accumulations per shot and a spectral resolution of
4 cm-1. Presented spectra are averages of 20–30 shots. In each figure, the baseline was adjusted
to zero and data points were joined with a smoothed line in Microsoft Excel. Although spectral
normalization was not possible, data were collected with the same instrument at the same time
from highly concentrated films of protein, and it can be expected that intensity differences
between samples originate in structural differences between conformers.

Ethics statement
All experiments involving mice in this study were conducted in accordance with protocol supa.
su.1 as reviewed and approved by Dartmouth College’s Institutional Animal Care and Use
Committee, operating under the regulations/guidelines of the NIH Office of Laboratory Animal Welfare (assurance number A3259-01).

Supporting Information
S1 Fig. Epitope mapping of cofactor and protein-only PrPSc protease-resistant cores. Western blots of mock and PK-digested PrPSc samples using mAb’s 6D11 (epitope comprising residues 93–109, with 97–100 as the major determinant of binding [1]) and R2 (epitope
comprising residues 224–230 [2], the extreme C-terminus of mature PrP) following purification to remove all soluble PrP digestion and/or degradation products.
(TIF)
S2 Fig. Western blot of cofactor and protein-only PrPSc samples subjected to structural
analysis by DXMS in Fig 2. By densitometry, 301C-seeded, ME7-seeded and OSU-seeded
cofactor PrPSc and OSU-seeded protein-only PrPSc have PK-resistant conversion efficiencies of
99, 82, 96 and 77%, respectively. Samples were purified as described and analyzed by DXMS.
The resulting solvent accessibility profiles are shown in Fig 2.
(TIF)
S3 Fig. DXMS purification of mock-seeded PMCA reactions recovers minimal proteasesensitive, insoluble PrP. To estimate the quantity of non-specifically aggregated PrP that could
potentially co-sediment during the purification of PrPSc samples for DXMS labeling, mockseeded PMCA reactions were performed using PMCA cocktail supplemented with brain-derived
cofactor or water. After 24 h of PMCA, the mock-seeded PMCA reactions were purified by ultracentrifugation as described, with proportional samples of the supernatant/pellet taken during
each of the three 100,000 rcf purification spins and analyzed by Western blot (labeled S1, P1, S2,
P2, S3, P3). Sample S0 denotes mock-seeded PMCA material after 24 h of intermittent sonication
and prior to ultracentrifugation. PK digestion was performed on the input and final pellet samples (S0 and P3, respectively) to determine protease resistance. Densitometry reveals that ~8% of

PLOS Pathogens | DOI:10.1371/journal.ppat.1005017 June 30, 2015

16 / 21

Comparison of Infectious & Non-Infectious Autocatalytic PrP Conformers

the mock-seeded sample becomes non-specifically aggregated in PMCA reactions containing
brain-derived cofactor (bottom panel, sample P3 vs S0). No non-specifically aggregated PrP was
detected in protein-only mock-seeded PMCA reactions (top panel, sample P3 vs S0).
(TIF)
S4 Fig. Regional solvent accessibility of α-PrP. 104 peptides, including different peptide
charge states, were recovered in two technical replicates and the average deuterium incorporation of overlapping peptides was used to determine regional solvent accessibility, as
described. Regions of NMR-assigned α-helix and β-strand structure are indicated by green spirals and black arrows, respectively [3].
(TIF)
S5 Fig. Regional solvent accessibility of an independent protein-only PrPSc sample. A sample of non-infectious PrPSc generated in a parallel sPMCA amplification to those samples analyzed in Fig 2 and S2 Fig was purified and subjected to hydrogen-deuterium exchange as
described. Regional solvent accessibility was determined from 226 recovered peptides, including different peptide charge states, as described.
(TIF)
S6 Fig. Kinetic curves of deuterium incorporation for individual PrPSc-derived peptides
(N-terminal to and including peptide aa160-168). 63 peptides, including different peptide
charge states, were identified in all DXMS technical replicates (n = 3 for 301C-seeded cofactor
PrPSc, orange triangles; n = 3 for ME7-seeded cofactor PrPSc, green squares; n = 3 for OSUseeded cofactor PrPSc, red circles; n = 2 for OSU-seeded protein-only PrPSc, blue diamonds).
Data points represent the mean fractional deuterium incorporation at a given labeling duration, with error bars representing the standard deviation. Data points were fit with a single
exponential function constrained to pass through the origin but without constraint on plateau
height (solid lines). For peptides in which a fit was not possible with the specified constraints,
data points are connected with straight dotted lines. S6 Fig includes deuterium incorporation
data for peptides N-terminal to and including the aa160-168 peptide.
(TIF)
S7 Fig. Kinetic curves of deuterium incorporation for individual PrPSc-derived peptides
(C-terminal to peptide aa160-168). 63 peptides, including different peptide charge states,
were identified in all DXMS technical replicates (n = 3 for 301C-seeded cofactor PrPSc, orange
triangles; n = 3 for ME7-seeded cofactor PrPSc, green squares; n = 3 for OSU-seeded cofactor
PrPSc, red circles; n = 2 for OSU-seeded protein-only PrPSc, blue diamonds). Data points represent the mean fractional deuterium incorporation at a given labeling duration, with error bars
representing the standard deviation. Data points were fit with a single exponential function
constrained to pass through the origin but without constraint on plateau height (solid lines).
For peptides in which a fit was not possible with the specified constraints, data points are connected with straight dotted lines. S7 Fig includes peptides C-terminal to the aa160-168 peptide.
(TIF)
S8 Fig. Raman spectroscopy of cofactor and protein-only PrPSc, focusing on spectral
regions assigned to CNH groups and tyrosine. Raman shifts corresponding to the ν(CN)
mode at ~3300 cm-1 and the ν(CN) and δ(CNH) modes in the Amide II region (~1530–
1580 cm-1) are shown, as well as a ν(CH) mode assigned to the tyrosine ring (~33075 cm-1).
The data presented spanning Raman shifts of 1500–1800 cm-1 is the same as that presented
in Fig 4, with different spectral information highlighted.
(TIF)
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S9 Fig. Biological replicate of deglycosylated PrPC sPMCA conversion using cofactor and
protein-only PrPSc seeds. Western blot showing three round sPMCA reactions using partially
purified and deglycosylated PrPC as the substrate and seeded with protein-only PrPSc, cofactor
PrPSc, or prion-infected brain homogenate, as indicated. This represents a biological replicate
of the experiment shown in Fig 5. All samples shown are from an identical exposure/image of a
single membrane, with irrelevant samples removed so that the experimental samples are adjacent to one another.
(TIF)
S1 References. Supporting Information references.
(DOCX)

Acknowledgments
We thank Prionics AG for generously providing 15B3 immunoprecipitation reagents.

Author Contributions
Conceived and designed the experiments: GPN DJW SL SS. Performed the experiments: GPN
DWW DJW SL. Analyzed the data: GPN DWW DJW JRB MBM SL SS. Contributed reagents/
materials/analysis tools: DJW MBM KAN SS. Wrote the paper: GPN DWW DJW JRB KAN SL
SS.

References
1.

Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95: 13363–13383. PMID: 9811807

2.

Kocisko DA, Come JH, Priola SA, Chesebro B, Raymond GJ, et al. (1994) Cell-free formation of protease-resistant prion protein. Nature 370: 471–474. PMID: 7913989

3.

Saborio GP, Permanne B, Soto C (2001) Sensitive detection of pathological prion protein by cyclic
amplification of protein misfolding. Nature 411: 810–813. PMID: 11459061

4.

Castilla J, Morales R, Saa P, Barria M, Gambetti P, et al. (2008) Cell-free propagation of prion strains.
Embo J 27: 2557–2566. doi: 10.1038/emboj.2008.181 PMID: 18800058

5.

Castilla J, Saa P, Hetz C, Soto C (2005) In vitro generation of infectious scrapie prions. Cell 121:
195–206. PMID: 15851027

6.

Deleault NR, Harris BT, Rees JR, Supattapone S (2007) Formation of native prions from minimal componenets in vitro. Proc Natl Acad Sci U S A 104: 9741–9746. PMID: 17535913

7.

Piro JR, Harris BT, Nishina K, Soto C, Morales R, et al. (2009) Prion protein glycosylation is not required
for strain-specific neurotropism. J Virol 83: 5321–5328. doi: 10.1128/JVI.02502-08 PMID: 19297485

8.

Piro JR, Harris BT, Supattapone S (2011) In situ photodegradation of incorporated polyanion does not
alter prion infectivity. PLoS Pathog 7: e1002001. doi: 10.1371/journal.ppat.1002001 PMID: 21304885

9.

Colby DW, Wain R, Baskakov IV, Legname G, Palmer CG, et al. (2010) Protease-sensitive synthetic
prions. PLoS Pathog 6: e1000736. doi: 10.1371/journal.ppat.1000736 PMID: 20107515

10.

Deleault NR, Walsh DJ, Piro JR, Wang F, Wang X, et al. (2012) Cofactor molecules maintain
infectious conformation and restrict strain properties in purified prions. Proc Natl Acad Sci U S A 109:
E1938–E1946. doi: 10.1073/pnas.1206999109 PMID: 22711839

11.

Kim JI, Cali I, Surewicz K, Kong Q, Raymond GJ, et al. (2010) Mammalian prions generated from
bacterially expressed prion protein in the absence of any mammalian cofactors. J Biol Chem 285:
14083–14087. doi: 10.1074/jbc.C110.113464 PMID: 20304915

12.

Legname G, Baskakov IV, Nguyen HO, Riesner D, Cohen FE, et al. (2004) Synthetic mammalian prions. Science 305: 673–676. PMID: 15286374

13.

Makarava N, Kovacs GG, Bocharova O, Savtchenko R, Alexeeva I, et al. (2010) Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol 119: 177–187.
doi: 10.1007/s00401-009-0633-x PMID: 20052481

14.

Timmes AG, Moore RA, Fischer ER, Priola SA (2013) Recombinant prion protein refolded with lipid and
RNA has the biochemical hallmarks of a prion but lacks in vivo infectivity. PLoS One 8: e71081. doi:
10.1371/journal.pone.0071081 PMID: 23936256

PLOS Pathogens | DOI:10.1371/journal.ppat.1005017 June 30, 2015

18 / 21

Comparison of Infectious & Non-Infectious Autocatalytic PrP Conformers

15.

Wang F, Wang X, Yuan CG, Ma J (2010) Generating a Prion with Bacterially Expressed Recombinant
Prion Protein. Science 327: 1132–1135. doi: 10.1126/science.1183748 PMID: 20110469

16.

Spinner DS, Kascsak RB, Lafauci G, Meeker HC, Ye X, et al. (2007) CpG oligodeoxynucleotideenhanced humoral immune response and production of antibodies to prion protein PrPSc in mice
immunized with 139A scrapie-associated fibrils. J Leukoc Biol 81: 1374–1385. PMID: 17379700

17.

Prusiner SB, Groth DF, Bolton DC, Kent SB, Hood LE (1984) Purification and structural studies of a
major scrapie prion protein. Cell 38: 127–134. PMID: 6432339

18.

Korth C, Stierli B, Streit P, Moser M, Schaller O, et al. (1997) Prion (PrPSc)-specific epitope defined by
a monoclonal antibody. Nature 390: 74–77. PMID: 9363892

19.

Bai Y, Milne JS, Mayne L, Englander SW (1993) Primary structure effects on peptide group hydrogen
exchange. Proteins 17: 75–86. PMID: 8234246

20.

Engen JR (2009) Analysis of protein conformation and dynamics by hydrogen/deuterium exchange
MS. Anal Chem 81: 7870–7875. doi: 10.1021/ac901154s PMID: 19788312

21.

Riek R, Hornemann S, Wider G, Billeter M, Glockshuber R, et al. (1996) NMR structure of the mouse
prion protein domain PrP(121–321). Nature 382: 180–182. PMID: 8700211

22.

Siamwiza MN, Lord RC, Chen MC, Takamatsu T, Harada I, et al. (1975) Interpretation of the doublet at
850 and 830 cm-1 in the Raman spectra of tyrosyl residues in proteins and certain model compounds.
Biochemistry 14: 4870–4876. PMID: 241390

23.

Edwards HG, Hunt DE, Sibley MG (1998) FT-Raman spectroscopic study of keratotic materials: horn,
hoof and tortoiseshell. Spectrochim Acta A Mol Biomol Spectrosc 54A: 745–757. PMID: 9679318

24.

Günzler H, Gremlich H-U (2002) IR spectroscopy: an introduction. Weinheim: Wiley-VCH. xiii, 361 p.
p.

25.

Caughey B, Raymond GJ, Bessen RA (1998) Strain-dependent differences in beta-sheet conformations of abnormal prion protein. J Biol Chem 273: 32230–32235. PMID: 9822701

26.

Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, et al. (1991) Secondary structure analysis of the
scrapie-associated protein PrP 27–30 in water by infrared spectroscopy. Biochemistry 30: 7672–7680.
PMID: 1678278

27.

Smirnovas V, Baron GS, Offerdahl DK, Raymond GJ, Caughey B, et al. (2011) Structural organization
of brain-derived mammalian prions examined by hydrogen-deuterium exchange. Nat Struct Mol Biol
18: 504–506. doi: 10.1038/nsmb.2035 PMID: 21441913

28.

Lu X, Wintrode PL, Surewicz WK (2007) Beta-sheet core of human prion protein amyloid fibrils as determined by hydrogen/deuterium exchange. Proc Natl Acad Sci U S A 104: 1510–1515. PMID: 17242357

29.

Nazabal A, Hornemann S, Aguzzi A, Zenobi R (2009) Hydrogen/deuterium exchange mass spectrometry identifies two highly protected regions in recombinant full-length prion protein amyloid fibrils. J Mass
Spectrom 44: 965–977. doi: 10.1002/jms.1572 PMID: 19283723

30.

Smirnovas V, Kim JI, Lu X, Atarashi R, Caughey B, et al. (2009) Distinct structures of scrapie prion protein (PrPSc)-seeded versus spontaneous recombinant prion protein fibrils revealed by hydrogen/deuterium exchange. J Biol Chem 284: 24233–24241. doi: 10.1074/jbc.M109.036558 PMID: 19596861

31.

Singh J, Udgaonkar JB (2013) Dissection of conformational conversion events during prion amyloid
fibril formation using hydrogen exchange and mass spectrometry. J Mol Biol 425: 3510–3521. doi: 10.
1016/j.jmb.2013.06.009 PMID: 23811055

32.

Miller MB, Wang DW, Wang F, Noble GP, Ma J, et al. (2013) Cofactor Molecules Induce Structural
Transformation during Infectious Prion Formation. Structure.

33.

Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, et al. (2014) Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat
Genet 46: 152–160. doi: 10.1038/ng.2853 PMID: 24336168

34.

Cobb NJ, Sonnichsen FD, McHaourab H, Surewicz WK (2007) Molecular architecture of human prion
protein amyloid: a parallel, in-register beta-structure. Proc Natl Acad Sci U S A 104: 18946–18951.
PMID: 18025469

35.

Groveman BR, Dolan MA, Taubner LM, Kraus A, Wickner RB, et al. (2014) Parallel In-register Intermolecular beta-Sheet Architectures for Prion-seeded Prion Protein (PrP) Amyloids. J Biol Chem 289:
24129–24142. doi: 10.1074/jbc.M114.578344 PMID: 25028516

36.

Paramithiotis E, Pinard M, Lawton T, LaBoissiere S, Leathers VL, et al. (2003) A prion protein epitope
selective for the pathologically misfolded conformation. Nat Med 9: 893–899. PMID: 12778138

37.

Taguchi Y, Mistica AM, Kitamoto T, Schatzl HM (2013) Critical significance of the region between Helix
1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein. PLoS
Pathog 9: e1003466. doi: 10.1371/journal.ppat.1003466 PMID: 23825952

PLOS Pathogens | DOI:10.1371/journal.ppat.1005017 June 30, 2015

19 / 21

Comparison of Infectious & Non-Infectious Autocatalytic PrP Conformers

38.

Muramoto T, Scott M, Cohen FE, Prusiner SB (1996) Recombinant scrapie-like prion protein of 106
amino acids is soluble. Proc Natl Acad Sci U S A 93: 15457–15462. PMID: 8986833

39.

Supattapone S, Bosque P, Muramoto T, Wille H, Aagaard C, et al. (1999) Prion protein of 106 residues
creates an artifical transmission barrier for prion replication in transgenic mice. Cell 96: 869–878.
PMID: 10102274

40.

Kurt TD, Bett C, Fernandez-Borges N, Joshi-Barr S, Hornemann S, et al. (2014) Prion transmission prevented by modifying the beta2-alpha2 loop structure of host PrPC. J Neurosci 34: 1022–1027. doi: 10.
1523/JNEUROSCI.4636-13.2014 PMID: 24431459

41.

Kurt TD, Jiang L, Bett C, Eisenberg D, Sigurdson CJ (2014) A proposed mechanism for the promotion
of prion conversion involving a strictly conserved tyrosine residue in the beta2-alpha2 loop of PrPC. J
Biol Chem 289: 10660–10667. doi: 10.1074/jbc.M114.549030 PMID: 24596090

42.

Sigurdson CJ, Nilsson KP, Hornemann S, Heikenwalder M, Manco G, et al. (2009) De novo generation
of a transmissible spongiform encephalopathy by mouse transgenesis. Proc Natl Acad Sci U S A 106:
304–309. doi: 10.1073/pnas.0810680105 PMID: 19073920

43.

Sigurdson CJ, Nilsson KP, Hornemann S, Manco G, Fernandez-Borges N, et al. (2010) A molecular
switch controls interspecies prion disease transmission in mice. J Clin Invest 120: 2590–2599. doi: 10.
1172/JCI42051 PMID: 20551516

44.

Hasnain SS, Murphy LM, Strange RW, Grossmann JG, Clarke AR, et al. (2001) XAFS study of the
high-affinity copper-binding site of human PrP(91–231) and its low-resolution structure in solution. J
Mol Biol 311: 467–473. PMID: 11493001

45.

Jackson GS, Murray I, Hosszu LL, Gibbs N, Waltho JP, et al. (2001) Location and properties of metalbinding sites on the human prion protein. Proc Natl Acad Sci U S A 98: 8531–8535. PMID: 11438695

46.

Jones CE, Abdelraheim SR, Brown DR, Viles JH (2004) Preferential Cu2+ coordination by His96 and
His111 induces beta-sheet formation in the unstructured amyloidogenic region of the prion protein. J
Biol Chem 279: 32018–32027. PMID: 15145944

47.

Hetz C, Mollereau B (2014) Disturbance of endoplasmic reticulum proteostasis in neurodegenerative
diseases. Nat Rev Neurosci 15: 233–249. doi: 10.1038/nrn3689 PMID: 24619348

48.

Hornemann S, Schorn C, Wuthrich K (2004) NMR structure of the bovine prion protein isolated from
healthy calf brains. EMBO Rep 5: 1159–1164. PMID: 15568016

49.

Kim JI, Surewicz K, Gambetti P, Surewicz WK (2009) The role of glycophosphatidylinositol anchor in
the amplification of the scrapie isoform of prion protein in vitro. FEBS Lett 583: 3671–3675. doi: 10.
1016/j.febslet.2009.10.049 PMID: 19854187

50.

Nishina KA, Supattapone S (2007) Immunodetection of glycophosphatidylinositol-anchored proteins
following treatment with phospholipase C. Anal Biochem 363: 318–320. PMID: 17321480

51.

Mitra N, Sinha S, Ramya TN, Surolia A (2006) N-linked oligosaccharides as outfitters for glycoprotein
folding, form and function. Trends Biochem Sci 31: 156–163. PMID: 16473013

52.

Chen PY, Lin CC, Chang YT, Lin SC, Chan SI (2002) One O-linked sugar can affect the coil-to-beta
structural transition of the prion peptide. Proc Natl Acad Sci U S A 99: 12633–12638. PMID: 12235358

53.

Stohr J, Elfrink K, Weinmann N, Wille H, Willbold D, et al. (2011) In vitro conversion and seeded fibrillization of posttranslationally modified prion protein. Biol Chem 392: 415–421. doi: 10.1515/BC.2011.
048 PMID: 21476870

54.

Cancellotti E, Mahal SP, Somerville R, Diack A, Brown D, et al. (2013) Post-translational changes to
PrP alter transmissible spongiform encephalopathy strain properties. EMBO J 32: 756–769. doi: 10.
1038/emboj.2013.6 PMID: 23395905

55.

Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, et al. (2005) Anchorless prion protein results in
infectious amyloid disease without clinical scrapie. Science 308: 1435–1439. PMID: 15933194

56.

Baron GS, Hughson AG, Raymond GJ, Offerdahl DK, Barton KA, et al. (2011) Effect of glycans and the
glycophosphatidylinositol anchor on strain dependent conformations of scrapie prion protein: improved
purifications and infrared spectra. Biochemistry 50: 4479–4490. doi: 10.1021/bi2003907 PMID:
21539311

57.

Bett C, Kurt TD, Lucero M, Trejo M, Rozemuller AJ, et al. (2013) Defining the conformational features of
anchorless, poorly neuroinvasive prions. PLoS Pathog 9: e1003280. doi: 10.1371/journal.ppat.
1003280 PMID: 23637596

58.

Chesebro B, Race B, Meade-White K, Lacasse R, Race R, et al. (2010) Fatal transmissible amyloid
encephalopathy: a new type of prion disease associated with lack of prion protein membrane anchoring. PLoS Pathog 6: e1000800. doi: 10.1371/journal.ppat.1000800 PMID: 20221436

59.

Raymond GJ, Race B, Hollister JR, Offerdahl DK, Moore RA, et al. (2012) Isolation of novel synthetic
prion strains by amplification in transgenic mice coexpressing wild-type and anchorless prion proteins.
J Virol 86: 11763–11778. doi: 10.1128/JVI.01353-12 PMID: 22915801

PLOS Pathogens | DOI:10.1371/journal.ppat.1005017 June 30, 2015

20 / 21

Comparison of Infectious & Non-Infectious Autocatalytic PrP Conformers

60.

Marshall KE, Offerdahl DK, Speare JO, Dorward DW, Hasenkrug A, et al. (2014) Glycosylphosphatidylinositol anchoring directs the assembly of Sup35NM protein into non-fibrillar, membrane-bound aggregates. J Biol Chem 289: 12245–12263. doi: 10.1074/jbc.M114.556639 PMID: 24627481

61.

Pankiewicz J, Prelli F, Sy MS, Kascsak RJ, Kascsak RB, et al. (2006) Clearance and prevention of
prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci 23: 2635–2647. PMID: 16817866

62.

Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RB, et al. (1998) Mapping the prion protein using
recombinant antibodies. J Virol 72: 9413–9418. PMID: 9765500

63.

Nishina KA, Deleault NR, Mahal SP, Baskakov I, Luhrs T, et al. (2006) The stoichiometry of host PrPC
glycoforms modulates the efficiency of PrPSc formation in vitro. Biochemistry 45: 14129–14139.
PMID: 17115708

64.

Deleault NR, Piro JR, Walsh DJ, Wang F, Ma J, et al. (2012) Isolation of phosphatidylethanolamine as
a solitary cofactor for prion formation in the absence of nucleic acids. Proc Natl Acad Sci U S A 109:
8546–8551. doi: 10.1073/pnas.1204498109 PMID: 22586108

PLOS Pathogens | DOI:10.1371/journal.ppat.1005017 June 30, 2015

21 / 21

